Clinical trials: Morquio Syndrome
Mucopolysaccharidosis IV A, Morquio A Syndrome
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
This Phase 3 extension study will evaluate the long-term efficacy and safety of BMN 110 2.0 mg/kg/week and/or BMN 110 2.0 mg/kg/every other week in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).
- Conditions
- Mucopolysaccharidosis IV A, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01415427
- Testing
- BMN 110 - Weekly, BMN 110 - Every Other Week
- Where
- 43 sites in United States, Argentina and 18 more
- Volunteers
- 173 people
- Sponsor
- BioMarin Pharmaceutical
Morquio B Disease, GM1 Gangliosidosis Type III
Natural History of Morquio B and Late-Onset of GM1 Gangliosidosis
Mucopolysaccharidosis type IVB (Morquio-B disease, MBD) is an autosomal-recessive lysosomal disease caused by mutations in a gene called GLB1.
- Trial name
- NCT04320329
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Head and Neck Cancer, Quality of Life
Effectiveness Verification of Using Hydrogen Inhalation to Improve Fatigue, Pain and Quality of Life in Cancer Patients
There are two recruitment methods for this study, which are mainly based on the Co-Principal Investigator Dr. Chih-Jen Huang recommendation of eligible subjects and poster recruitment methods.
- Conditions
- Head and Neck Cancer, Quality of Life, Pain, Sleep
- Trial name
- hydrogen (NCT05728112)
- Testing
- Hydrogen Inhalation, Ordinary Air Inhalation
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital